Parvovirus structural protein for the treatment of autoimmune diseases
Assignee2A Pharma AB
InventorJeanette Prangsgaard
Life of this patent
Estimating the term…
Abstract
The present invention relates to a mutated parvovirus structural protein, comprising at least one insertion comprising a sequence of at least six consecutive amino acids comprised within amino acids 320 to 641 of human HSP70i. Furthermore, the invention relates to multimeric structures comprising the protein, VLPs, a method of producing the mutated parvovirus structural protein and to medicaments or vaccines comprising the mutated parvovirus structural protein that may be used for treating vitiligo or other autoimmune diseases.
Claims16
A method of treating or preventing an autoimmune and/or inflammatory disease, or a method of immunosuppression, wherein the method comprises administering a mutated parvovirus structural protein to a subject in need thereof, wherein the mutated parvovirus structural protein comprises at least one insertion comprising an amino acid sequence of at least six consecutive amino acids within amino acids 320 to 621 of human HSP70i.
Dependencies are inferred from the claim text.